Investor Presentaiton slide image

Investor Presentaiton

Stevanato Group - 70 years of Operational Excellence Leading Provider of Mission-Critical Solutions for the Biopharma Industry Track Record of Growth Global Partner of Choice ~5,600 ~700 Top 25 € 1,085M + 10% employees globally customers in 2023 pharma companies² FY23 Revenue yoy Revenue Growth Market Leader³ #1 #1 #2 26.9% FY23 adj. EBITDA margin¹, ~ € 945M YE23 Backlog Ready-to-Use Vials Pen Cartridges Pre-Filled Syringes +670bps vs 2019 SG, Stevanato Group ¹Adjusted operating profit margin, adjusted net profit, adjusted DEPS, adjusted EBITDA and adjusted EBITDA margin, Net Debt, CapEx, Free Cash Flow are non-GAAP financial measures. Please refer to slides 37 to 46 for a reconciliation of non-GAAP measures. 2 As measured by 2022 revenue, according to data collected by Pharmacircle and public companies' information 3 Estimated market position in 2022, based on available market data and internal estimates and assumptions of peer CAGR increasing at or below the market rate. Stevanato Group Investor Presentation, March 2024 4
View entire presentation